The abstract is read at the publisher; the summary is JClub's.
Microalgal systems are positioned as a promising route for industrial monoclonal antibody production, leveraging light-driven growth and low-cost media to enable significant scalability.
- Why it matters: High operational and capital costs of Chinese hamster ovary cells limit broader market access, motivating alternatives that still fit regulatory expectations for high-value, modest-scale therapeutics.
- What they did: The work reviews the history of mAb production in microalgae and highlights recent molecular and bioprocessing advances that could support industrial-scale manufacturing.
- The result: Lower production costs and increased scale are expected to open new market opportunities beyond the therapeutic space, contingent on access to lower-cost mAbs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.